Otsuka Beijing Research Institute
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2003-08-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.obri.com.cn
Clinical Trials
33
Active:2
Completed:30
Trial Phases
5 Phases
Phase 1:10
Phase 2:5
Phase 3:12
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
Phase 3
12 (36.4%)Phase 1
10 (30.3%)Phase 2
5 (15.2%)Phase 4
4 (12.1%)Not Applicable
2 (6.1%)Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT07105124
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Phase 1
Active, not recruiting
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06091267
- Locations
- 🇨🇳
The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
- Interventions
- Drug: placebo
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 87
- Registration Number
- NCT05923892
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
Phase 3
Completed
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Drug: 1% OPA-15406 OintmentOther: 0% OPA-15406 Vehicle
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 270
- Registration Number
- NCT05667623
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing Municipality, China
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
Phase 3
Completed
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Drug: 0.3% OPA-15406 OintmentDrug: 1% OPA-15406 OintmentOther: 0% OPA-15406 vehicle
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 240
- Registration Number
- NCT05650320
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found